13 results about "Receptorome" patented technology

The embodiment of the invention relates to the technical field of drug detection, in particular to an anti-CD38 antibody drug receptor occupation detection method and system, a peripheral blood sample is used for preparing a single-cell suspension, the single-cell suspension is divided into a TEST tube and an FMO tube, a cell surface antibody and an RO detection antibody are added into the TEST tube, only the cell surface antibody is added into the FMO tube, and only the RO detection antibody is added into the FMO tube. The TEST tube and the FMO tube are subjected to sample detection analysis, so that the average fluorescence intensity of RO detection antibodies of the TEST tube and the FMO tube is obtained. And performing RO detection analysis by adopting a dissociation method, taking the tubes which are not combined with the medicine as a total receptor group, taking the tubes which are combined with the medicine as a dissociation receptor group, and calculating an RO detection result according to the average fluorescence intensity of the TEST tube and the FMO tube.

Provided are compositions and method for prophylaxis and / or therapy of hearing loss or related dysfunctions, including but not limited to tinnitus, that could be ameliorated by restoring central nervous system inhibitory synapses. The compositions include polynucleotides and viral vectors that are used to express at least one GABA receptor component which may be a GABAA receptor alpha 1 subunit or GABAR receptor Ib subunit. Expression of the GABA receptor may be under control of a CaMKII promoter.

The present invention provides a chimeric antigen receptor (CAR) system comprising; (i) a receptor component comprising a antigen binding domain and a first binding domain; and (ii) a signalling component comprising a signalling domain and a second binding domain which binds the single domain binder of the first binding domain of the receptor component wherein either the first or second binding domains comprise a single domain binder, and wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent, the receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain; whereas in the presence of the agent, the receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.

Disclosed are compositions comprising dominant negative chimeric tumor necrosis factor receptor 1 (TNFR1) fusion proteins and methods for use in cell therapies.

Provided herein are multiplexed T cell receptor compositions, combination therapies, and uses thereof.

This invention relates to compositions and methods for modifying Cytokinin Receptor Histidine Kinase (HK) genes in plants, optionally to improve yield traits, the HK genes encoding a histidine kinase (HK) polypeptide. The invention further relates to plants having increased improved yield traits produced using the methods and compositions of the invention.

The application discloses a spoke-shaped decellularized cornea and a preparation method and application thereof, and belongs to the technical field of biomaterials and tissue engineering. The application realizes an orderly process of the phase change of water molecules along the temperature gradient direction by establishing a gradient temperature field from the periphery to the center of a sheet-shaped biological corneal tissue, and forms spoke-shaped microchannels in the cornea. The spoke-shaped microchannels can accelerate the decellularization process of the central region of the cornea, avoid excessive decellularization of the peripheral region of the cornea to cause excessive loss of bioactive components of the extracellular matrix, form a biomimetic migration path between the cornea and the receptor, facilitate the migration and infiltration of the cells of the receptor tissue into the cornea, promote the biological healing of the transplanted cornea and the limbus of the receptor cornea, and improve the biological stability of the transplanted cornea.

The application discloses a kind of biological sensors for detecting serum miRNA-21 of cervical cancer patient, it is related to the technical field of biosensor.The biological sensor of the application utilizes the large specific surface area of UiO-66-NH2, and Ru (bpy) 3 2+ Molecule (energy donor) and Ag nanoparticle (energy acceptor) are assembled in the same UiO-66-NH2, so that it exhibits high-efficiency intramolecular RET-ECL effect, enhances the ECL sensing response; Based on the stand point mediated strand displacement reaction and catalytic hairpin self-assembly signal amplification strategy, the diversity of substrate selection and the sensitivity of detection are improved; The catalysis of biological enzyme is used to improve the accuracy and timeliness of the biosensor. The biosensor of the application can be applied to the sensitive determination of miRNA-21 in the serum of cervical cancer patients, and has important application value.

This invention relates to compositions and methods for modifying Cytokinin Receptor Histidine Kinase (HK) genes in plants, optionally to improve yield traits, the HK genes encoding a histidine kinase (HK) polypeptide. The invention further relates to plants having increased improved yield traits produced using the methods and compositions of the invention.

The invention discloses a biosensor for detecting serum miRNA-21 of a cervical cancer patient, and relates to the technical field of biosensors. According to the biosensor disclosed by the invention, the Ru (bpy) 3 < 2 + > molecules (energy donors) and the Ag nanoparticles (energy receptors) are assembled in the same UiO-66-NH2 by utilizing the relatively large specific surface area of the UiO-66-NH2, so that the biosensor shows an efficient intramolecular RET-ECL effect, and the ECL sensing response is enhanced; based on a foothold mediated strand displacement reaction and a catalytic hairpin self-assembly signal amplification strategy, the diversity of substrate selection and the sensitivity of detection are improved; the accuracy and timeliness of the biosensor are improved by utilizing catalysis of the biological enzyme. The biosensor provided by the invention can be applied to sensitive determination of miRNA-21 in serum of cervical cancer patients, and has important application value.

The present application relates to PD-1 switch receptors, e.g., chimeric PD-1 switch receptors, in combination with a FAS dominant negative receptor, optionally in combination with a safety switch, e.g., truncated EGFR, which can be used in adoptive cell therapy to treat human diseases and disorders.

The present application relates to PD-1 switch receptors, e.g., chimeric PD-1 switch receptors, in combination with a FAS dominant negative receptor, optionally in combination with a safety switch, e.g., truncated EGFR, which can be used in adoptive cell therapy to treat human diseases and disorders.

A method for differential drug discovery involves obtaining a receptor panel which specifies a multitude of targets and a multitude of anti-targets. The method further involves obtaining a small molecule compound (SMC) seed model and derivatizing a first multitude of candidate SMCs from the SMC seed model. For each of the candidate SMCs in the first multitude of candidate SMCs, first desired interactions between the candidate SMC and each of the multitude of targets are simulated, and first undesired interactions between the candidate SMC and each of the multitude of anti-targets are simulated. The method also involves obtaining a first SMC interaction score for each of the candidate SMCs in the first multitude of candidate SMCs based on the first desired interactions and the first undesired interactions, and based on the first SMC interaction score, determining whether at least a minimum score for a drug is reached.